Welcome To ZEESOL

We produce comprehensive IV fluids in multiple-size packings to make them accessible per required IV therapy. Our products play an integral role in acute and chronic treatments.

Vision

To become a global leader in developing the best IV infusions while prioritising accessibility and affordability for patients worldwide.

Mission

Zeesol aims to collaborate with distributors and institutions committed to spreading wellness and bringing a meaningful difference in IV infusion treatments.

About Us

The Project is ideally located 18 Km from Hasan Abdal on Main Hazara Trunk Road in District Haripur. The Plant is based in 44.3 Kanals., serving the nation for decades. Three families own a non-public limited company;

  1. Ashfaq Safdar Tarar (CEO)
  2. Sh. Zulqar Hussain (Chairman)
  3. Dr. Ijaz Ahmed (Late) (DirectorOperations)

All families have a leading role in the company, backed by a dynamic team of professional experts who resolve to: “Serve the Ailing Humanity with a futuristic vision and meet the demands of a rapidly changing health scenario through Service, Devotion, and Dedication!”

Why IV infusions?

IV (Intravenous) fluids are specifically formulated medicines and nutrients directly injected into a patient’s vein in various medical treatments. IV infusions help the medication or the nutrients to access the body more rapidly through the circulatory system. That is why, through mild to chronic medical treatments, their usage is not so uncommon for medical caretakers.

Depending on the individual’s need and medical treatment, some of the IV infusion uses are briefly listed;

Antibiotic infusion

Fluid Replacement Infusion

Chemotherapy Infusion

TPN (Total Parenteral Nutri)on)

Blood transfusion

Our Products

We produce comprehensive IV fluids in multiple-size packings to make them accessible per required IV therapy. Our products play an integral role in acute and chronic treatments. Our international market coverage assists us in being more responsive in the local market while continually improving our across-the-border product offerings.